Aethlon Medical Receives Ethics Approval For Clinical Trial Of Hemopurifier In Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical has received ethics approval to conduct a clinical trial of its Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 therapy. The trial will take place at Pindara Private Hospital in Queensland, Australia.
August 12, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical has received ethics approval for a clinical trial of its Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 therapy. This regulatory milestone could positively impact the stock in the short term.
The ethics approval for the clinical trial is a significant regulatory milestone for Aethlon Medical. It indicates progress in their product development and could lead to positive investor sentiment, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100